The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2020 | Retrospective analysis of COVID-19 infection in CLL patients
Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, discusses the risk of COVID-19 infection and chronic lymphocytic leukemia (CLL). Cases were collected all over the world in a retrospective study. It was found that patients with CLL did not contract COVID-19 at a higher rate than the general population, but were more likely to suffer from more severe infections. Treatment with BTK-inhibitors also displayed protective qualities. Patients who were not undergoing treatment were associated with more severe COVID-19 infections. This interview took place during the European Research Initiative on CLL (ERIC) International Virtual Meeting 2020.
